Endometrium

BGOG-en-6

A Phase 3, Randomized, Double-blind, Multicenter Study Comparing TSR-042 plus Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin plus Placebo in Patients with Recurrent or Advanced Endometrial Cancer Who Had Received no Previous Systemic Anticancer therapy for Advanced or Metastatic Disease

Sponsor: GSK/Tesaro

Participating sites:

  • UZ Leuven, Leuven
  • CHU de Liège, site Sart Tilman, Liège
  • OLV Aalst, Aalst

Learn More ->

BGOG-en-9

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

  • UZ Leuven, Leuven
  • CHU UCL St-Luc, Bruxelles
  • UZ Antwerpen, Antwerpen
  • AZ Maria Middelares, Gent
  • AZ Delta, Roeselare

Learn More ->

BGOG-en-10

Randomized, Multi-Center, Double Blind Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer

Sponsor:  AstraZeneca

Participating sites:

  • UZ Leuven, Leuven
  • UZ Gent, Gent
  • CHU UCL St-Luc, Bruxelles
  • Hôpital de Libramont, Libramont
  • AZ Groeninge, Kortrijk
  • AZ Sint Jan Brugge, Brugge
  • Grand Hôpital de Charleroi, Charleroi
  • Clinique CHC Montlégia, Liège
  • Jessa Ziekenhuis, Hasselt

Learn More ->

BGOG-EN-5

An Investigator-Sponsored Randomized Phase III Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer 

Learn More ->